Value of Screening and Treatment of SAHS in the Management of AF Ablation Candidates
Recruiting · NCT04606693 · Interventional (participants receive a specific treatment) · Lead sponsor: Hospital San Carlos, Madrid
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
The present prospective cohort study (not randomized) analyses the value of screening and treatment of SAHS in the management of patients with AF refractory to antiarrhythmics drugs, potentially candidates for ablation. Patients at low risk of suffering from SAHS will follow conventional management of their AF, according to the usual criteria of the Arrhythmia Unit. Patients with high or intermediate risk of SAHS, will undergo respiratory polygraphy. If the result is positive, they will be treated as standard for this syndrome and their heart rate will be monitored for 3 months. After this, the patient's arrhythmic load will be reevaluated differentiating patients into two groups, those that must be ablated from those that have improved their condition and the clinical criteria is no longer ablation but follow-up.
Who can take part
Inclusion criteria
- Patients with paroxysmal or persistent atrial fibrillation
- Recurrent atrial fibrillation despite treatment with at least one class I or III antiarrhythmic
- No previous diagnosis of apnea-hypopnea syndrome
Exclusion criteria
- Patients \<18 years
- Pregnant women
- Doubts about the patient's ability to perform a home respiratory polygraphy
- Doubts about the patient's ability to acquire rhythm records with the Kardia system (smartphone required)
- Unavailability for follow-up at our center for at least 1 year.
Where it is running
1 location listed.
- Hospital Clínico San Carlos - Madrid, Madrid, Spain